移植物抗宿主疾病 (GVHD) 市场 - 按疾病类型、治疗类型、年龄层、给药途径、配销通路- 全球预测 2024 - 2032 年

由于越来越多地采用造血干细胞移植（HSCT）程序，特别是在血液恶性肿瘤和自体免疫疾病的治疗方面，移植物抗宿主疾病（GVHD）市场规模预计在2024年至2032年期间复合年成长率为8.1%。根据美国国立卫生研究院的数据，每年约进行 5 万例干细胞移植，年增率在 10% 至 15% 之间。由于HSCT仍然是多种疾病的重要治疗方式，GVHD的发生率预计将相应上升。医疗技术和移植手术的快速进步提高了移植受者的存活率。

医疗保健提供者和患者意识的提高进一步凸显了早期检测和及时干预在 GVHD 管理中的重要性。及时诊断可以启动适当的治疗策略，从而降低 GVHD 的严重程度并改善患者的预后。正在进行的研发活动专注于开发具有改善功效和安全性的新型疗法，这将进一步推动市场扩张。

GVHD产业分为疾病类型、治疗类型、年龄层、给药途径、配销通路和地区。

根据治疗类型，由于皮质类固醇具有强大的抗发炎和免疫抑制特性，预计到 2032 年，其市场规模将以 7.8% 的速度成长。皮质类固醇有多种剂型，包括口服、静脉注射和外用製剂，可提供给药灵活性，并可根据 GVHD 表现的严重程度和部位制定量身定制的治疗方法。

就给药途径而言，移植物抗宿主疾病市场的口服部分预计在 2024 年至 2032 年期间复合年增长率为 8.4%。口服药物为患者提供方便和易于给药，确保临床环境之外的自我管理并促进对治疗方案的依从性。这种可近性提高了患者的依从性，同时改善了治疗结果和整体生活品质。

亚太地区移植物抗宿主疾病产业在 2024 年至 2032 年期间将以 8.5% 的复合年增长率实现令人瞩目的成长。这可以归因于造血干细胞移植（HSCT）手术发生率的上升，特别是在医疗基础设施不断发展和移植服务获得改善的国家。当地医疗机构、製药公司和研究组织之间不断加强的合作正在促进针对临床需求的新型 GVHD 疗法的开发，进一步刺激区域市场的成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 血液疾病盛行率增加
    • 移植技术的进步
    • 研发投资不断增加
    • 不断增长的治疗药物管线
  • 产业陷阱与挑战
    • 治疗费用高
    • 严格的监管挑战
    • 併发症和復发的风险
• 成长潜力分析
• 管道分析
• 监管环境
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪錶板

第 5 章：市场估计与预测：按疾病类型，2021 - 2032

• 主要趋势
• 急性移植物抗宿主疾病（aGVDH）
• 慢性移植物抗宿主疾病（cGVDH）

第 6 章：市场估计与预测：按治疗类型，2021 - 2032 年

• 主要趋势
• 单株抗体
• mTOR抑制剂
• 酪胺酸激酶抑制剂
• 免疫抑制剂
• 皮质类固醇
• 其他治疗类型

第 7 章：市场估计与预测：按年龄划分，2021 - 2032

• 主要趋势
• < 20 年
• 21-50岁
• 51岁以上

第 8 章：市场估计与预测：按管理途径，2021 - 2032 年

• 主要趋势
• 口服
• 静脉
• 专题

第 9 章：市场估计与预测：按配销通路划分，2021 - 2032 年

• 主要趋势
• 医院药房
• 零售药局
• 网路药局

第 10 章：市场估计与预测：按地区，2021 - 2032

• 主要动向：按地区
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 中东和非洲其他地区

第 11 章：公司简介

• Astellas Pharma Inc.
• Bristol Myers Squibb
• ElsaLys Biotech SA
• Incyte Corporation
• Johnson & Johnson Services, Inc.
• Kiadis Pharma
• Mallinckrodt Pharmaceuticals
• Merck & Co., Inc.
• Mesoblast Ltd
• Neovii Pharmaceuticals AG
• Novartis AG
• Pfizer Inc.
• Sanofi
• Soligenix

Graft versus host disease (GVHD) market size is estimated to register 8.1% CAGR between 2024 to 2032, driven by the increasing adoption of hematopoietic stem cell transplantation (HSCT) procedures, particularly in the treatment of hematologic malignancies and autoimmune disorders. As per National Institute of Health, approximately 50,000 stem cell transplants are conducted annually, experiencing an annual growth rate ranging between 10% to 15%. As HSCT remains a crucial treatment modality for various diseases, the incidence of GVHD is expected to rise correspondingly. Rapid advancements in medical technology and transplant procedures have led to improved survival rates among transplant recipients.

Increased awareness among healthcare providers and patients is further outlining the importance of early detection and prompt intervention in GVHD management. Timely diagnosis allows the initiation of appropriate treatment strategies, thereby reducing the severity of GVHD and improving patient outcomes. The ongoing R&D activities focused on the development of novel therapeutics with improved efficacy and safety profiles will further propel the market expansion.

The GVHD industry is segmented into disease type, treatment type, age group, route of administration, distribution channel and region.

Based on treatment type, the market size from the corticosteroids segment is anticipated to witness 7.8% growth rate through 2032, due to their potent anti-inflammatory and immunosuppressive properties. Corticosteroids are widely available in various formulations, including oral, intravenous, and topical preparations for offering flexibility in administration and enabling tailored treatment approaches based on the severity and site of GVHD manifestations.

With regards to route of administration, the oral segment in the graft versus host diseases market is anticipated to observe 8.4% CAGR during 2024-2032. Oral medications offer patients convenience and ease of administration ensuring self-management outside of clinical settings and promoting adherence to treatment regimens. This accessibility is enhancing patient compliance while leading to improved treatment outcomes and overall quality of life.

Asia Pacific graft versus host disease industry will record impressive growth at 8.5% CAGR over 2024-2032. This can be attributed to the rising incidence of hematopoietic stem cell transplantation (HSCT) procedures, particularly in countries with growing healthcare infrastructure and improved access to transplant services. Rising collaborations between local healthcare institutions, pharmaceutical companies, and research organizations is fostering the development of novel GVHD therapies tailored to the clinical needs, further stimulating the regional market growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of hematological disorders
    • 3.2.1.2 Advancements in transplantation techniques
    • 3.2.1.3 Rising investments in research and development
    • 3.2.1.4 Growing pipeline of therapeutic agents
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High treatment cost
    • 3.2.2.2 Stringent regulatory challenges
    • 3.2.2.3 Risk of complications and relapse
• 3.3 Growth potential analysis
• 3.4 Pipeline analysis
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Million)

• 5.1 Key trends
• 5.2 Acute graft versus host disease (aGVDH)
• 5.3 Chronic graft versus host disease (cGVDH)

Chapter 6 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Million)

• 6.1 Key trends
• 6.2 Monoclonal antibodies
• 6.3 mTOR inhibitors
• 6.4 Tyrosine kinase inhibitors
• 6.5 Immunosuppressants
• 6.6 Corticosteroids
• 6.7 Other treatment types

Chapter 7 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Million)

• 7.1 Key trends
• 7.2 < 20 years
• 7.3 21-50 years
• 7.4 51 years and above

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Million)

• 8.1 Key trends
• 8.2 Oral
• 8.3 Intravenous
• 8.4 Topical

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Million)

• 9.1 Key trends
• 9.2 Hospital pharmacies
• 9.3 Retail pharmacies
• 9.4 Online pharmacies

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Million)

• 10.1 Key trends, by region
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 Astellas Pharma Inc.
• 11.2 Bristol Myers Squibb
• 11.3 ElsaLys Biotech SA
• 11.4 Incyte Corporation
• 11.5 Johnson & Johnson Services, Inc.
• 11.6 Kiadis Pharma
• 11.7 Mallinckrodt Pharmaceuticals
• 11.8 Merck & Co., Inc.
• 11.9 Mesoblast Ltd
• 11.10 Neovii Pharmaceuticals AG
• 11.11 Novartis AG
• 11.12 Pfizer Inc.
• 11.13 Sanofi
• 11.14 Soligenix